



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/989,731	11/20/2001	Avi J. Ashkenazi	P2730P1C70	2397

35489 7590 05/13/2004

HELLER EHRMAN WHITE & MCAULIFFE LLP
275 MIDDLEFIELD ROAD
MENLO PARK, CO 94025-3506

EXAMINER

HAMUD, FOZIA M

ART UNIT	PAPER NUMBER
----------	--------------

1647

DATE MAILED: 05/13/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/989,731

Applicant(s)

ASHKENAZI ET AL.

Examiner

Fozia M Hamud

Art Unit

1647

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 25 August 2003.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 119-138 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 119-138 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

1. Applicant's preliminary amendment canceling claims 1-118 and adding new claims 119-138, filed on 15 November 2001 is acknowledged.

Thus claims 119-138 are pending and under consideration.

Priority:

2a. Based on the information given by Applicants and an inspection of the patent applications, the Examiner has concluded that the subject matter defined in this application is supported by the disclosure in application serial no. 09/941,992, filed on 28 August 2001. Application serial no. 09/941,992 discloses the claimed PRO1245 nucleic acid as SEQ ID NO:407, and also demonstrates that PRO1245 DNA was higher in primary lung tumors and in primary colon tumors compared to DNA isolated from normal controls. Accordingly, the subject matter defined in instant claims 119-138, is afforded an effective filing date of 08/28/01, which is the filing date of the U.S.

Application NO: 09/941,992.

Should the applicant disagree with the examiner's factual determination above, it is incumbent upon the applicant to provide the serial number and specific page number(s) of any parent application filed prior to 08/28/01, which specifically supports the particular claim limitation for each and every claim limitation in all the pending claims which applicant considers to have been in possession of and fully enabled for prior to 08/28/01.

Information Disclosure Statement:

Art Unit: 1647

3a. The information disclosure statements filed 31 May 2002 fails to comply with the provisions of 37 CFR 1.97, 1.98 and MPEP § 609 because they fail to identify each reference by author and publication date. The references have been placed in the application file, but the information referred to therein has not been considered as to the merits. Applicant is advised that the date of any re-submission of any item of information contained in this information disclosure statement or the submission of any missing element(s) will be the date of submission for purposes of determining compliance with the requirements based on the time of filing the statement, including all certification requirements for statements under 37 CFR 1.97(e). See MPEP § 609 C(1).

Specification:

4a. The lengthy specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant's cooperation is requested in correcting any errors of which applicant may become aware in the specification.

Claim Rejections - 35 U.S.C. § 112:

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

5a. Claims 119-128, 132-138 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for an isolated nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO:407, a vector comprising said nucleic

Art Unit: 1647

acid, an isolated host cell comprising said vector, does not reasonably provide enablement for an isolated nucleic acid encoding the polypeptide of SEQ ID NO:408 or variants of SEQ ID NO:407. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

Instant claims 119, 120, 121, 122, 123 are drawn to nucleic acid having 80%, 85%, 90%, 95% and 99% to a nucleic acid encoding the polypeptide of SEQ ID NO:408, however, instant specification does not teach how to make or use said nucleic acid. The instant specification discloses a gene amplification assay (Example 170 on page 539 and on the table on pages 552 and 553), which demonstrates that PRO1245 DNA was higher in primary lung tumors and in primary colon tumors compared to DNA isolated from normal controls. Therefore, only SEQ ID NO:407 (full length) can be used for diagnostic purposes, because Applicants have not shown that any other nucleic acid or variant, even degenerate variants encoding the same protein was higher in tumor samples as compared to normal samples. Thus, while the nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO:407, (full length) may be used to detect cancer cells due to increased copy number, the increased copy number of SEQ ID NO:407 does not provide a readily apparent use for all nucleic acids comprising the nucleotide sequences encoding the polypeptide of SEQ ID NO:408, or variants of the nucleic acid of SEQ ID NO:407, because there is no information regarding whether degenerate variants encoding the same protein, were increased in cancer tumors compared to normal controls.

Art Unit: 1647

Furthermore, it is not clear from the specification what types of mutations are allowed in the single, full length probe (i.e SEQ ID NO:407) used in the diagnostic assay without loss of probe specificity, therefore, instant specification does not teach how to use an isolated nucleic acid comprising a nucleotide sequence, which hybridizes less than the full length of SEQ ID NO:407.

The data in the instant specification shows that gene copy number is increased in certain tumor tissue samples, however, it does not necessarily follow that an increase in gene copy number results in increased gene expression and increased protein expression, such that "all possible" nucleic acids encoding the polypeptide of SEQ ID NO:408, or other variants of the nucleic acid of SEQ ID NO:407, would be useful diagnostically or as target for cancer drug development. For example, Pennica et al, (1998, PNAS USA 95:14717-14722) discloses that, "An analysis of WISP-1 gene amplification in human colon tumors showed a correlation between DNA amplification and over expression, whereas, over expression of WISP-3 RNA was seen in the absence of DNA amplification. In contract, WISP-2 DNA was amplified in the colon tumors, but mRNA expression was significantly reduced in the majority of tumors compared with the expression in normal colonic mucosa from the same patient", see page 14722, second paragraph of column 1; pages 14720-14721. Therefore, the protein levels cannot be accurately predicted from the level of the corresponding gene. Thus only the full length PRO1245 nucleic acid (SEQ ID NO:407) of the instant invention would be useful in a diagnostic manner, but not the nucleic acid encoding the polypeptide of SEQ ID NO:408 or variants of the nucleic acid of SEQ ID NO:407.

Art Unit: 1647

Thus, while instant specification is enabling for an isolated nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO:407, the specification is non enabling for an isolated nucleic acid encoding the polypeptide of SEQ ID NO:408 or variants of the nucleic acid of SEQ ID NO:407. Due to the large quantity of experimentation necessary to determine "all" possible variants of the nucleic acid of SEQ ID NO:407 that would encode the polypeptide of SEQ ID NO:408, and to screen an activity/property for said polypeptide, the lack of direction/guidance presented in the specification regarding which variants of the nucleic acid of SEQ ID NO:407 are elevated in tumor samples compared to normal controls, the complex nature of the invention, the state of the prior art establishing that the protein levels cannot be accurately predicted from the level of the corresponding gene, the unpredictability of the effects of mutation on the structure and function of the claimed nucleic acid, and the breadth of the claims which fail to recite particular biological activities, undue experimentation would be required of the skilled artisan to make and/or use the claimed invention in its full scope.

5b. Claims 1 19-124 and 132-138 are also rejected under 35 U.S.C. 1 12, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor, at the time the application was filed, had possession of the claimed invention.

The claims are directed to nucleic acids which encode a polypeptide of SEQ ID NO:408. Further claim limitations are presented to isolated nucleic acids having at least 80%, 85%, 90%, 95%, 99% sequence identity to a nucleic acid encoding the

Art Unit: 1647

polypeptide of SEQ ID NO: 408, or the polypeptide of SEQ ID NO: 408 lacking its associated signal peptide. Claims are also presented encompassing vectors and cells comprising nucleic acids having at least 80%, 90%, 95% , 99% sequence identity to SEQ ID NO: 407.

However, the specification teaches a nucleic acid (SEQ ID NO: 407) and a polypeptide (SEQ ID NO: 408). The specification does not teach functional or structural characteristics of all the claimed nucleic acids. The description of one nucleic acid encoding a PRO polypeptide (SEQ ID NO: 408) is not adequate written description of an entire genus of functionally equivalent nucleic acids and polypeptides.

To provide evidence that Applicants were in possession of the claimed genus, the specification must provide sufficient distinguishing identifying characteristics of the genus. The factors to be considered include disclosure of complete or partial structure, physical and/or chemical properties, functional characteristics, structure/function correlation, methods of making the claimed product, or any combination thereof. In this case, the only factor present in the claim is a partial structure in the form of a recitation of percent identity. There is not even identification of any particular portion of the structure that must be conserved. Accordingly, in the absence of sufficient recitation of distinguishing identifying characteristics, the specification does not provide adequate written description of the claimed genus.

Vas-cath Inc. v. Mahurkar, 19USPQ2d 1111, clearly states that applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the

Art Unit: 1647

written description' inquiry, whatever is now claimed" (See page 1 117). The specification does not clearly allow persons of ordinary skill in the art to recognize that (he or she) invented what is claimed" (See Vas-cath at page 1116).

With the exception of the sequences referred to above, the skilled artisan cannot envision the detailed chemical structure of all claimed nucleic acids, and therefore, would not know how to use them. Conception is not achieved until reduction to practice has occurred, regardless of the complexity or simplicity of the method of use. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method of use. The nucleotide itself is required. See *Fiers v. Revel*, 25 USPQ 2d 1601 at 1606 (CAFC 1993) and *Amgen Inc. v. Chugai Pharmaceutical Co. Ltd.*, 18 USPQ2d 1 1016. One cannot describe what one has not conceived.

Therefore, only an isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 407, but not the full breadth of the claims, meets the written description provision of 35 U.S.C. 1 12, first paragraph. Applicant is reminded that Vas-cath makes clear that the written description provision of 35 U.S.C. 1 12 is severable from its enablement provision (see page 1 115).

Claim Rejections - 35 U.S.C. § 112, second paragraph:

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

6. Claims 132-134 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

6a. Claims 132 and 133 are drawn to a nucleic acid, which hybridizes to another nucleic acid under stringent conditions. However, the claims are vague and indefinite because the claims fail to recite the specific stringent hybridizations conditions. This rejection could be obviated by supplying specific conditions supported by the specification, which Applicants consider to be "stringent".

Claim 134 is also rejected under 35 U.S.C. § 112, second paragraph, as being indefinite, so long as it depends from claim 133 for the limitations set forth directly above.

Claim rejections-35 USC § 102(b):

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

7a. Claims 119-138 are rejected under 35 U.S.C § 102(b) as being anticipated by GENENTECH INC. (GETH), (WO 99/63088, December/1999); DIADEXUS LLC. (DIAD), (WO 99/60160 November/1999); INCYTE (INCY), (WO 00/00610, June/2000).

Each of references, GETH, DIADA and INCY, discloses an isolated nucleic acid which encodes a polypeptide that shares 100% amino acid sequence identity to the

Art Unit: 1647

amino acid sequence of the polypeptide of SEQ ID NO:408 of the instant application.

See attached copies of the comparison of SEQ ID NOs:408, of the instant invention and the sequences of the references (SEQUENCE COMPARISON 'A', 'B', 'C').

Regarding claim 131, it is understood that the deposited sequence encodes the polypeptide of SEQ ID NO:408, therefore, since the nucleic acid disclosed by each of the above references encodes a polypeptide that shares 100% identity to the polypeptide of SEQ ID NO:408, these references also anticipate claim 131. With respect to claims 132 and 133, the nucleic acid disclosed by each of the references would be expected to hybridize to the claimed nucleic acid. With respect to claims 126 and 128, the WO 99/6308 discloses a nucleic acid which encodes the polypeptide of SEQ ID NO:408, lacking its associated signal peptide, (see claim 26 of the world patent WO 99/6308).

Therefore the GETH, DIAD and INCY references, all anticipate the instant claims 119-125, 129-131 in the absence of any evidence to the contrary.

8. No claim is allowed.

Advisory Information:


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Fozia M Hamud whose telephone number is (571) 272-0884. The examiner can normally be reached on Monday, Thursday-Friday, 6:00 am to 4:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary L Kunz can be reached on (571) 272-0887. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1647

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Fozia Hamud
Patent Examiner
Art Unit 1647
06 May 2004



JANET ANDRES
PATENT EXAMINER